Haleos Labs Seeks Shareholder Approval for ₹20 Crore Subsidiary Guarantee

Haleos Labs is asking shareholders to vote on a corporate guarantee that will back a significant loan for its subsidiary, Mahi Drugs Private Limited. The proposed guarantee covers an External Commercial Borrowing (ECB) of USD 2.2 million, approximately ₹20 Crore, from RBL Bank. This transaction is classified as a Material Related Party Transaction, requiring investor consent.

Shareholders will cast their votes via postal ballot from March 31, 2026, to April 29, 2026. The results are expected to be announced on May 1, 2026.

Why this matters

The corporate guarantee aims to help Mahi Drugs secure the USD 2.2 million loan on potentially favorable terms. This funding is intended to support the subsidiary's operations and working capital, ultimately strengthening its financial position. A robust subsidiary can contribute positively to Haleos Labs' overall financial performance.

Company Background

Haleos Labs Limited operates in the pharmaceutical sector, specializing in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates. It also offers contract manufacturing services.

Key Changes and Implications

If approved, Haleos Labs will provide an irrevocable guarantee for Mahi Drugs' loan from RBL Bank. This gives the subsidiary access to necessary credit for its operations. The decision represents a material financial commitment for Haleos Labs, indirectly linking its consolidated financial risk to Mahi Drugs' borrowing obligations.

Potential Risks

• Haleos Labs will become liable for the entire loan amount if Mahi Drugs defaults on its ECB obligations to RBL Bank.
• The classification as a Material Related Party Transaction highlights significant financial exposure, requiring careful monitoring.
• Specific directors—Mr. TVVSN Murthy, Mr. T.V. Praveen, and Mrs. Sudeepthi Gopineedi—have an interest in this resolution, which is standard for RPTs but noted.

Industry Context

Operating in the API manufacturing and contract services space, Haleos Labs competes with other pharmaceutical companies such as Aarti Drugs Ltd, Granules India Ltd, and Laurus Labs Ltd. These companies face similar market pressures, including raw material costs, regulatory hurdles, and global demand fluctuations.

Subsidiary Performance Metrics

• Mahi Drugs Private Limited reported transactions totaling ₹3,661.08 lakh in FY 2024-25.
• For the first three quarters of FY26, its year-to-date transactions reached ₹2,501.14 lakh.
• As of February 2025, the subsidiary held a stable credit rating of IVR BB+ from Infomerics.

What to Watch Next

• The outcome of the shareholder vote is the immediate trigger.
• Actual utilization and deployment of the ECB funds by Mahi Drugs will be critical.
• Mahi Drugs' ability to service its debt and meet repayment obligations to RBL Bank.
• Any further disclosures related to the subsidiary's performance or related party transactions.